<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611271</url>
  </required_header>
  <id_info>
    <org_study_id>2015-11-Studienanmeldung</org_study_id>
    <nct_id>NCT02611271</nct_id>
  </id_info>
  <brief_title>Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy</brief_title>
  <official_title>Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients With Sepsis and Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytokine adsorption using the cytosorb adsorber is currently investigated to reduce the
      levels of proinflammatory cytokines in patients with severe sepsis and septic shock. The
      adsorber is frequently used in series with continuous renal replacement therapy. Up to date,
      no data on the removal of antibiotic drugs during combined renal replacement therapy and
      cytokine adsorptive therapy is available. Therefore, we want to investigate

      - whether and to what extent antibiotic drugs (piperacillin/tazobactam and
      imipenem/cilastatin) are removed during combined continuous renal replacement therapy and
      cytosorb adsorption in patients with severe sepsis and septic shock
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in this trial are undergoing renal replacement therapy as part of their routine
      care. Thus, this is an observational trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Removal of antibiotic drugs during the first 8 hours of combined continuous renal replacement therapy and cytosorb adsorption</measure>
    <time_frame>8 hours</time_frame>
    <description>Removal of antibiotic drugs during combined CRRT and adsorption will be evaluated by calculating total filter clearance using the drug concentration pre- and postfilter as well as the dialysate concentration. The adsorptive clearance will be evaluated using the pre- and postadsorber concentration. The outcome measure will be removal of antibiotic drug [mg/8 h dosing interval].</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Critical Illness</condition>
  <condition>Sepsis</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Piperacillin/Tazobactam</arm_group_label>
    <description>Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipenem/Cilastatin</arm_group_label>
    <description>Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Monitoring of antibiotic drug removal</intervention_name>
    <description>No study specific intervention will be performed</description>
    <arm_group_label>Piperacillin/Tazobactam</arm_group_label>
    <arm_group_label>Imipenem/Cilastatin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients treated for sepsis on surgical intensive care unit undergoing renal
        replacement therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intensive care patients with severe sepsis or septic shock and acute kidney injury
             requiring continuous renal replacement therapy and cytokine adsorption

          -  Age &gt; 18 y

        Exclusion Criteria:

          -  &lt; 18 y

          -  Pregnancy

          -  Contraindications against citrate-anticoagulation or continuous renal replacement
             therapy or cytokine adsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Detlef Kindgen-Milles, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Duesseldorf University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Detlef Kindgen-Milles, Prof.</last_name>
    <phone>+49 211 81</phone>
    <phone_ext>07047</phone_ext>
    <email>Kindgen-Milles@med.uni-duesseldorf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Interdisziplinäre Intensivstation ZOM 1, UKD</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Detlef Kindgen-Milles, Prof.</last_name>
      <phone>0049 211 81</phone>
      <phone_ext>07047</phone_ext>
      <email>Kindgen-Milles@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Anästhesiologie</investigator_full_name>
    <investigator_title>Prof. D. Kindgen-Milles</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

